[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 2004

Use of SCORTEN to Accurately Predict Mortality in Patients With Toxic Epidermal Necrolysis in the United States

Arch Dermatol. 2004;140(7):890-892. doi:10.1001/archderm.140.7.890

The SCORTEN is an illness severity score specific to toxic epidermal necrolysis (TEN) developed and validated in Europe by Bastuji-Garin et al.1 Recently, 2 reports of the use of the SCORTEN toassess the changes in mortality in patients treated with intravenous immune globulin have shown contradictory results, bringing into question the applicabilityof the SCORTEN outside Europe.2,3 We therefore retrospectively analyzed our patients with TEN before using intravenousimmune globulin to determine whether the SCORTEN would accurately predict mortality.

First Page Preview View Large
First page PDF preview
First page PDF preview